Komai Kan, Nishida Takashi
Dept. of Gynecology and Obstetrics, Kurume University School of Medicine, 67 Asahi-machi, Krume 830-0011, Japan.
Gan To Kagaku Ryoho. 2002 Mar;29(3):481-6.
The current role of tumor markers in the management of ovarian cancer is reviewed. The most useful tumor marker in epithelial ovarian cancer is still the antigen CA125. However, the level of this marker is modified by peritoneal irritation from endometriosis or inflammatory disease. Furthermore, the level is not elevated in nearly half of patients with the stage I disease, suggesting a limited value as a screening marker. In CA125 positive cases, the marker determination is a sensitive indicator in the early diagnosis of progressive disease in ovarian cancer. The lack of an effective second-line regimen, however, limits the value of the antigen as monitoring marker. Expectations for the new tumor markers lysophosphatidic acid and inhibin are also briefly discussed.
本文综述了肿瘤标志物在卵巢癌管理中的当前作用。上皮性卵巢癌中最有用的肿瘤标志物仍是抗原CA125。然而,该标志物的水平会受到子宫内膜异位症或炎症性疾病引起的腹膜刺激的影响。此外,近一半的I期疾病患者该标志物水平并未升高,这表明其作为筛查标志物的价值有限。在CA125阳性病例中,标志物测定是卵巢癌进展性疾病早期诊断的敏感指标。然而,缺乏有效的二线治疗方案限制了该抗原作为监测标志物的价值。文中还简要讨论了对新肿瘤标志物溶血磷脂酸和抑制素的期望。